Although the supporting mechanisms responsible for the persistence of memory T cells remains still controversial, a robust and sustainable intrahepatic CD8+ T cell response is the target of the vaccine designs aimed at avoiding the intrahepatic development of malaria blood-stage merozoite forms, which are ultimately responsible for the clinical signs of the disease. This evidence concerns the gene CD8A and malaria.